Form 8-K PROGENICS PHARMACEUTICAL For: Sep 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Progenics Pharmaceuticals (PGNX) Sell-Off 'Seems Overdone' - BTIG
September 13, 2018 11:53 AM EDTBTIG analyst Timothy Chiang said the sell-off in Progenics Pharmaceuticals (NASDAQ: PGNX) on 1404 Phase 2 results "seems overdone".
Chiang commented, "We believe this mornings weakness in PGNX shares creates a potential buying opportunity. While the shares are currently down meaningfully (~16%) following the Co.s release of... More
